rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Vivos Therapeutics, Inc.

VVOS · Nasdaq

Health CareMedical DevicesNot moving yet

VVOS stood above a rising 150-day average in 0 of the last 52 weekly readings. It is 76.6% below that average now. Medical Devices: 27% of its 181 stocks in an uptrend (−9 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 52
Industry in uptrend
27% -9 in 4 wk
Insider buys, 12 months
$3.6M
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
22 (+1)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 52 weeks.

17 Apr – 16 Oct
19%29%40%Apr 26Jun 26Jul 26Sep 26Oct 26

Medical Devices: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
$0$3.5MNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months2
Sale orders, 12 months0
Buyers · sellers2 · 0
WhoDidSharesTraded
Michael C. Skaff10% ownerbought859,166at $0.58230 Jun 2026filed 15 Jul 2026
Michael C. Skaff10% ownerbought1,890,164at $0.58230 Jun 2026filed 15 Jul 2026
Michael C. Skaff10% ownerbought2,749,330at $0.58230 Jun 2026filed 15 Jul 2026
Michael C. Skaff10% ownerbought1,044,777at $1.3431 Mar 2026filed 2 Apr 2026
Michael C. Skaff10% ownerbought308,848at $1.3431 Mar 2026filed 2 Apr 2026
Michael C. Skaff10% ownerbought429,957at $1.3431 Mar 2026filed 2 Apr 2026
Michael C. Skaff10% ownerbought1,783,582at $1.3431 Mar 2026filed 2 Apr 2026
Michael C. Skaff10% ownerbought1,783,582at $1.3431 Mar 2026filed 2 Apr 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders22+1 on the quarter
New · exited5 · 4
Reported value$243K

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
GEODE CAPITAL MANAGEMENT, LLCreduced · filed 12 Aug 202685,001$39K-10,542−11.0%
IHT Wealth Management, LLCadded · filed 14 Aug 202676,736$35K+35,675+86.9%
VANGUARD CAPITAL MANAGEMENT LLCnew · filed 13 Aug 202660,629$28K+60,629
COMMONWEALTH EQUITY SERVICES, LLCunchanged · filed 29 Jul 202642,500$19K00.0%
UBS Group AGadded · filed 13 Aug 202639,154$18K+28,108+254.5%
B. Riley Wealth Advisors, Inc.unchanged · filed 14 Jul 202638,066$19K00.0%
Centurion Wealth Management LLCunchanged · filed 9 Jul 202635,684$16K00.0%
BlackRock, Inc.unchanged · filed 7 Aug 202627,817$13K00.0%
STATE STREET CORPunchanged · filed 7 Aug 202624,922$11K00.0%
Sequoia Financial Advisors, LLCunchanged · filed 17 Jul 202624,000$11K00.0%
31 Dec 2023 – 30 Jun 2026
131822Dec 23Sep 24Mar 25Dec 25Jun 26

Everyone who traded it

Gregg C. Johnson Company insiderDirector · last 14 Sep 20260 · 0
Leonard J. Sokolow Company insiderDirector · last 14 Sep 20260 · 0
Bradford K. Amman Company insiderPrincipal Accounting Officer · last 31 Jul 20262 · 0
Michael C. Skaff Company insider10% owner · last 30 Jun 20261 · 0
Ronald Kirk Huntsman Company insiderChief Executive Officer · last 30 Jun 202612 · 0
V-Co Investors 3 Llc Company insider10% owner · last 31 Mar 20261 · 0
Anja B. Krammer Company insiderDirector · last 20 Jun 20240 · 0
Mark F. Lindsay Company insiderDirector · last 20 Jun 20240 · 0
Matthew Thompson Company insiderDirector · last 20 Jun 20240 · 0
Ralph Elias Green Company insiderDirector · last 20 Jun 20240 · 0
Gurdev Dave Singh Company insiderChief Medical Officer · last 5 Aug 20210 · 0

Same industry

RCEL Avita MedicalLeading+100%
ATRC AtriCureLeading+49%
HAE HaemoneticsLeading+48%
HTFL HeartflowLeading+40%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202560.4%
Operating profit marginFY 2025 · to 31 Dec 2025-114%
Free cash flow marginFY 2025 · to 31 Dec 2025-101%
Interest coverFY 2025 · to 31 Dec 2025-14.21×
Research spendFY 2025 · to 31 Dec 20250.6%
Share count trendFY 2025 · to 15 Apr 202645.2%
Cash and equivalentsFY 2025 · to 31 Dec 2025$2.0M
Free cash flowFY 2025 · to 31 Dec 2025−$17.6M

Analyst forecasts

No analyst forecasts yet.